^
    1d
    Targeting CDK12 rescues C/EBPβ-mediated platinum and PARP inhibitor resistance in ovarian cancer. (PubMed, Cell Signal)
    Elevated C/EBPβ expression enhanced cisplatin resistance and olaparib resistance. Targeting C/EBPβ via CDK12 inhibition could rescue drug responsiveness of ovarian cancer, thereby counteracting platinum and PARP inhibitor resistance. C/EBPβ could thus be exploited as a candidate prognostic biomarker in ovarian cancer.
    Journal • PARP Biomarker
    |
    CDK12 (Cyclin dependent kinase 12)
    |
    Lynparza (olaparib) • cisplatin
    1d
    Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial (clinicaltrials.gov)
    P1/2, N=63, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • etoposide IV
    2d
    PNOC017: BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (clinicaltrials.gov)
    P1, N=78, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH2 mutation
    |
    temozolomide • Partruvix (pamiparib)
    4d
    Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, AHS Cancer Control Alberta | Trial primary completion date: Jul 2027 --> Apr 2028
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MGMT (6-O-methylguanine-DNA methyltransferase) • BRCA (Breast cancer early onset)
    |
    Lynparza (olaparib) • temozolomide
    4d
    A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer (clinicaltrials.gov)
    P1/2, N=16, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jul 2027 --> Dec 2025 | Trial primary completion date: Jul 2027 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    temozolomide • Talzenna (talazoparib)
    4d
    Study Evaluating Safety, Tolerability, and Metabolism of Niraparib (clinicaltrials.gov)
    P4, N=70, Recruiting, University of Miami | Trial completion date: Oct 2030 --> Mar 2031 | Trial primary completion date: Oct 2028 --> Mar 2029
    Trial completion date • Trial primary completion date
    |
    Zejula (niraparib)
    4d
    Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Nov 2025 --> Apr 2026 | Trial primary completion date: Nov 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    4d
    Safety and efficacy of Cisplatin in combination with Sintilimab and Niraparib in patients with advanced solid tumors: A phase Ib study. (PubMed, Cancer Pathog Ther)
    Further validation in larger, histology-specific patients is needed to confirm clinical benefit. https://www.chictr.org.cn/; ID: ChiCTR1900024488.
    P1 data • Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • Tyvyt (sintilimab) • Zejula (niraparib)
    8d
    Rucaparib in refractory pleural mesothelioma harboring somatic pathogenic BRCA1 and BRCA2 mutation. A report of two cases. (PubMed, Lung Cancer Manag)
    Targeted agents did not demonstrate a significant clinical benefit in mesothelioma treatment, nevertheless a small group of patients might harbor potentially actionable somatic mutations, as in homologous repair recombination genes. In this paper we report two cases of patients with heavily pretreated pleural mesothelioma that had a relevant clinical benefit with rucaparib treatment based on somatic BRCA 1 and BRCA 2 mutations detected through next generation sequencing.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Rubraca (rucaparib)
    8d
    Drug combination discovery assisted by AI and untargeted metabolomics: pamiparib and anlotinib synergistic potentiation for ovarian cancer treatment. (PubMed, Front Pharmacol)
    In vivo, significant downregulation of p-PI3K, p-Akt, Bcl-2, and HIF1-α, and upregulation of BAX protein expression confirmed that the mechanism of action of combination therapy is related to PI3K/Akt pathway. The combination of PAM and ANL was more effective than monotherapy for treating ovarian cancer and holds potential to become a new therapeutic approach for ovarian cancer.
    Journal • PARP Biomarker • IO biomarker • Metabolomic study
    |
    BCL2 (B-cell CLL/lymphoma 2) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • BAX (BCL2-associated X protein) • ANXA5 (Annexin A5)
    |
    Focus V (anlotinib) • Partruvix (pamiparib)
    8d
    Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Hebei Medical University Fourth Hospital | Trial completion date: Sep 2024 --> Sep 2031 | Trial primary completion date: Sep 2023 --> Sep 2030
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative
    |
    Lynparza (olaparib)